A panel of experts which advises the Food and Drug Administration (FDA) has unanimously voted to recommend approval of a pioneering cancer therapy from Novartis, setting up a likely approval for the first-of-its-kind treatment. The FDA doesn't have to follow advisory panels' recommendations. But it usually does—especially when the vote is as lopsided Wednesday's was (10-0).
